文献速递核素与放射性配体治疗

177Lu肽受体放射性核素治疗神经内分泌肿瘤疗效的荟萃分析

Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2019-01-01

按RECIST标准,汇总疾病缓解率为29.1%(95%CI 20.2%-38.9%),疾病控制率为74.1%(95%CI 67.8%-80.0%);按SWOG标准,缓解率为30.6%(95%CI 20.7%-41.5%),控制率为81.1%(95%CI 76.4%-85.4%)。结论认为177Lu-PRRT诱导治疗(通常4次)是有效方法。

要点

  • 177Lu-PRRT诱导治疗不可切除转移性NET,RECIST缓解率29.1%、控制率74.1%。
  • SWOG标准下缓解率30.6%、控制率81.1%,与RECIST结果一致。

核心结论

  • 177Lu-PRRT诱导治疗(通常4次)对不可切除转移性神经内分泌肿瘤有效,疾病缓解率和控制率显著。

研究设计与样本

  • 其中11项研究1268例采用RECIST标准评估,6项研究804例采用SWOG标准评估。
  • 采用固定效应和随机效应模型计算汇总疾病缓解率和疾病控制率。

主要发现

  • RECIST标准下随机效应模型汇总疾病缓解率为29.1%(95%CI 20.2%-38.9%),疾病控制率为74.1%(95%CI 67.8%-80.0%)。
  • SWOG标准下随机效应模型汇总疾病缓解率为30.6%(95%CI 20.7%-41.5%),疾病控制率为81.1%(95%CI 76.4%-85.4%)。

关键数值与推荐

  • 疗效评估采用RECIST 1.0或1.1、改良RECIST、SWOG或改良SWOG标准。
  • RECIST标准汇总缓解率29.1%(95%CI 20.2%-38.9%),控制率74.1%(95%CI 67.8%-80.0%)。
  • SWOG标准汇总缓解率30.6%(95%CI 20.7%-41.5%),控制率81.1%(95%CI 76.4%-85.4%)。

临床怎么用

  • 对于不可切除转移性神经内分泌肿瘤,177Lu-PRRT诱导治疗(通常4次)可作为有效治疗选择。
  • 疗效评估可参照RECIST或SWOG标准,两者汇总缓解率和控制率结果相近。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to assess the efficacy of Lu-labeled peptide receptor radionuclide therapy (PRRT) induction treatments for patients with unresectable metastatic neuroendocrine tumors. METHODS: MEDLINE, EMBASE, and Ovid were systematically searched with keywords "lutetium," "Lu-177," "PRRT," "neuroendocrine," and "prognosis." Studies evaluating treatment with Lu-labeled PRRT were assessed for disease response and/or disease control rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 or 1.1, modified RECIST, Southwest Oncology Group (SWOG), or modified SWOG criteria. Pooled proportions of disease response and control rates were calculated for both fixed- and random-effects models. RESULTS: Eighteen studies with 1920 patients were included (11 with 1268 patients using RECIST and 6 with 804 patients using SWOG). By RECIST criteria, the pooled disease response rate by random-effects model was 29.1% (95% confidence interval [CI], 20.2%-38.9%), and disease control rate was 74.1% (95% CI, 67.8%-80.0%). By SWOG criteria, the pooled disease response rate by random-effects model was 30.6% (95% CI, 20.7%-41.5%), and disease control rate was 81.1% (95% CI, 76.4%-85.4%). CONCLUSIONS: Induction therapy, typically 4 treatments, with Lu PRRT is an effective method of treating unresectable metastatic neuroendocrine tumors with significant disease response and control rates.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Saravana-Bawan B, Bajwa A, Paterson J, et al. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis. Clin Nucl Med. 2019. PMID: 31205149. doi:10.1097/RLU.0000000000002646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。